Please ensure Javascript is enabled for purposes of website accessibility

3 Marijuana Stocks That Could Be Millionaire-Makers

By Keith Speights - Feb 2, 2020 at 9:00AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

These pot stocks have what it takes to deliver massive returns.

Any stock theoretically holds the potential to make you a millionaire. But few actually do. Stocks with the greatest likelihood of building fortunes tend to have small market caps and huge market opportunities. 

Cannabis definitely offers a huge market opportunity. The global cannabis market could expand close to tenfold over the next 10 to 15 years. Many players in the cannabis industry remain small and have a lot of room to grow as the market opportunities unfold. Which marijuana stocks can investors buy right now that hold the potential to be millionaire-makers? Here are three that I think are at the top of the list.

Cannabis leaf on top of a pile of $100 bills

Image source: Getty Images.

1. Valens 

Valens (VLNCF 29.39%) is a virtual lock to profit in a big way as the global cannabis market expands, in my view. The company provides services to extract cannabinoids such as CBD and THC from cannabis plants.

It's a pretty safe bet that the demand for cannabis extraction will soar over the next few years. The Cannabis 2.0 cannabis derivatives market in Canada is just getting started. Products including cannabis-infused beverages and foods as well as vapes are expected to rack up billions of dollars in sales. In the U.S., the legalization of hemp in late 2018 should drive increased demand for products containing hemp-derived CBD.

Valens is set to be a major winner in Canada's Cannabis 2.0 market and could make significant headway into the U.S. market, too. It boasts the highest extraction capacity in the industry. The company's customers include many of the biggest names in the business --Canopy Growth, HEXO, Organigram (OGI 3.91%), Tilray, and more. With a market cap of around $350 million, I think that Valens should deliver massive returns over the next decade.

2. Organigram

One of Valens' customers should also achieve tremendous success in the not-too-distant future. Organigram isn't the largest cannabis producer in Canada, but it's arguably the best.

Most of the major Canadian cannabis producers are struggling to establish a clear path to profitability. Organigram, though, appears to be in a good position to become profitable after its stellar fiscal 2020 first-quarter results announced a few weeks ago. The company's low cultivation costs and fiscal discipline put Organigram in the top tier of cannabis producers. Its market cap of around $450 million -- lower than most of its key rivals -- makes Organigram a better bargain.

Several factors should fuel Organigram's growth. The company's sales should soar as the Cannabis 2.0 market in Canada picks up steam. Ontario, Canada's most heavily populated province, is opening more retail stores throughout 2020. I also wouldn't be surprised if a large consumer packaged goods company partners with Organigram, opening the door for the cannabis producer to more effectively reach the global cannabis market.   

3. Innovative Industrial Properties

With a market cap of over $1.2 billion, Innovative Industrial Properties (IIPR 2.15%) is a good bit bigger than Valens and Organigram. However, I think that IIP remains small enough to provide huge returns over the next few years -- just as it has done over the last three years.

IIP is the largest cannabis-focused real estate investment trust (REIT). It acquires properties and leases them to medical cannabis operators in deals that free up cash flow for tenants and provides an ongoing revenue stream to IIP. So far, the company has 48 properties in 15 states. But that number will almost certainly continue to grow rapidly.

There are currently 18 states with legal medical cannabis markets that IIP hasn't entered yet and more states are likely to vote to legalize medical cannabis in November. The cannabis markets in many of the states were the company already operates are still in their early stages. IIP also has a big opportunity in expanding its relationships with existing multistate cannabis operators such as Cresco Labs

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

OrganiGram Holdings Stock Quote
OrganiGram Holdings
OGI
$1.33 (3.91%) $0.05
Innovative Industrial Properties Stock Quote
Innovative Industrial Properties
IIPR
$136.03 (2.15%) $2.87
The Valens Company Stock Quote
The Valens Company
VLNCF
$0.88 (29.39%) $0.20
Canopy Growth Stock Quote
Canopy Growth
CGC
$5.89 (2.79%) $0.16
Tilray Stock Quote
Tilray
TLRY
HEXO Stock Quote
HEXO
HEXO
$0.33 (3.11%) $0.01
Cresco Labs Inc. Stock Quote
Cresco Labs Inc.
CRLBF
$3.90 (-0.89%) $0.04

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
338%
 
S&P 500 Returns
119%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/17/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.